NeuroStar Effectiveness

Clinical trials have proven the effectiveness of NeuroStar TMS Therapy® in treating patients with major depression who have not benefited from prior antidepressant medication.* In clinical trials NeuroStar TMS Therapy was studied in adult patients suffering from Major Depressive Disorder, all of whom had not received satisfactory improvement with previous antidepressant medication.

In clinical trials, indicated patients had been treated with a median of four antidepressant medication attempts, one of which was at an adequate dose and duration.

Neurostar TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current episode.

NeuroStar TMS Therapy has not been studied in patients who have not received prior antidepressant treatment. Across the more than 400 Neurostar TMS Treatment centers in the U.S. many patients without previous antidepressant trials have benefited from the treatment. However, since the Neurostar TMS technology is so new, formal studies have not been conducted on this population.

Its effectiveness has also not been established in patients who have failed to receive benefit from two or more prior antidepressant medications at minimal effective dose and duration in the current episode. Neurostar TMS providers nationwide are reporting that this group of prospective patients is highly responsive to the treatment, but we do not yet have the benefit of formal research results. At Southern Colorado TMS Center, most of our first year patients have had at least two previous antidepressant trials of adequate dose and duration before learning about TMS treatment. We are pleased to cautiously report a very positive response rate

An Effective Option for Treating Major Depressive Disorder

In a controlled clinical trial comparing active treatment with the NeuroStar TMS Therapy® system to an inactive device, patients treated with active NeuroStar TMS Therapy experienced a 22.1% average reduction of their depression symptoms, compared to a 9% average reduction of depression symptoms in patients receiving inactive treatment.1

Patients treated with NeuroStar® also experienced significant improvement in anxiety and physical symptoms (such as appetite changes, aches and pains, and lack of energy) associated with depression.2

In a study most like real world clinical practice where all patients received active treatment, approximately half of the patients treated with NeuroStar TMS Therapy experienced significant improvement in their depression symptoms. About a third of the patients treated with NeuroStar TMS Therapy experienced complete symptom relief at the end of six weeks.

Data on file.
Demitrack MA, Thase ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharm Bull. 2009, 42(2): 5-38.

To schedule an appointment or for more information about how SCTMSC and TMS Therapy might be a good fit for you, please visit our NEXT STEP page.

For more information please see "Contact Us" page.

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s